Aurobindo Pharma today said it has got the final approval from the US drug regulator to market its antibiotic Cefotaxime injection used for treating various infections.
The company has received final approvals from the US Food & Drug Administration (USFDA) for two abbreviated new drug applications (ANDAs)--Cefotaxime for Injection in the strength of 1g, 2g and Cefotaxime for Injection in 10g (pharmacy bulk pack) dose, Aurobindo Pharma said in a statement to the Bombay Stock Exchange (BSE).
Cefotaxime is the generic version of global drug major Sanofi Aventis' Claforan injection.
The products are ready for launch, the Hyderabad-based drug maker said.
With these approvals, Aurobindo Pharma now has 109 ANDA approvals, which includes both tentative and final, from the USFDA.
Shares of Aurobindo Pharma today closed at Rs 819.30, up 0.33 per cent from its previous close on the BSE.
